BridgeBio Oncology Therapeutics Inc (BBOT) — Titan Protect Analysis

BBOT

BridgeBio Oncology Therapeutics Inc

Healthcare · ·

$7.81

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$646M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.76

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-62.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About BridgeBio Oncology Therapeutics Inc

Company description not available.

Country: USA Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.000

Positive but modest risk-adjusted returns

Kelly Fraction

-0.2446

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.237

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-10.5%

Historical annualised return based on price data

Max Drawdown

-44.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

123

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.22

Very low correlation to market moves

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.92

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.71

Moderate leverage — manageable

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-86,092,128

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-154,095,008

Loss-making — spending exceeds revenue after all costs

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
27 May2026	Josh Gottheimer	Democrat	sell	1K–15K
2026-04-13	Ro Khanna	Democrat	Sale	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go